Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of V260 (RotaTeq) in Healthy Infants in Korea
NCT00166517Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2005
- Primary completion
- Jul 2006
- Modality
- Live Biotherapeutic Products, Vaccines & Immunotherapeutics
01
Overview
Phase 3, randomised, double-blind trial in rotavirus infection comparing RotaTeq with Placebo (2 arms). Primary endpoint: Serum Anti-Rotavirus IgA Response. Started Aug 2005; status: completed.
02
Drugs
rotavirus vaccine, live, oral, pentavalent
03
Conditions
rotavirus infection
Beyond the preview
Go deeper on NCT00166517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00166517.